BeyondSpring (NASDAQ:BYSI) Stock Passes Below 50-Day Moving Average – Should You Sell?

BeyondSpring Inc. (NASDAQ:BYSI) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.53 and traded as low as $1.46. BeyondSpring shares last traded at $1.49, with a volume of 12,878 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

BeyondSpring Stock Down 3.2%

The stock’s 50-day moving average price is $1.53 and its 200 day moving average price is $1.76. The firm has a market cap of $60.09 million, a price-to-earnings ratio of -9.93 and a beta of 0.56.

Institutional Trading of BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC lifted its position in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 16.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 368,682 shares of the company’s stock after purchasing an additional 53,198 shares during the quarter. Geode Capital Management LLC owned approximately 0.91% of BeyondSpring worth $601,000 as of its most recent filing with the Securities and Exchange Commission. 40.29% of the stock is currently owned by hedge funds and other institutional investors.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.